Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAMADOL HYDROCHLORIDE vs PHRENILIN WITH CAFFEINE AND CODEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.
Combination analgesic; butalbital is a barbiturate that potentiates GABA-A activity; acetaminophen inhibits cyclooxygenase (COX) and modulates cannabinoid receptors; caffeine is a nonselective adenosine receptor antagonist; codeine is a prodrug converted to morphine, a mu-opioid agonist.
Management of moderate to moderately severe pain (FDA-approved),Off-label: neuropathic pain, restless legs syndrome, osteoarthritis pain, fibromyalgia
Relief of tension headache,Management of pain (off-label)
50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).
1-2 capsules orally every 4 hours as needed, not to exceed 8 capsules per day. Each capsule contains butalbital 50 mg, caffeine 40 mg, and codeine phosphate 30 mg.
5-6 hours (parent drug); 7-9 hours (M1 active metabolite). In renal impairment, half-life prolonged up to 11 hours (parent) and 17 hours (M1).
Butalbital: 35–50 hours; codeine: 2.5–3.5 hours; caffeine: 4–6 hours (adults), prolonged in liver disease. Clinical context: butalbital's long half-life leads to accumulation with repeated dosing; codeine's short half-life requires frequent dosing.
Extensively metabolized via O- and N-demethylation in the liver primarily by cytochrome P450 2D6 (CYP2D6) and CYP3A4, producing active metabolite O-desmethyltramadol (M1).
Butalbital: hepatic (CYP2C19); Acetaminophen: hepatic (CYP1A2, CYP2E1, conjugation); Caffeine: hepatic (CYP1A2); Codeine: hepatic via CYP2D6 to morphine; also metabolized by CYP3A4 to norcodeine.
Primarily renal (90% total clearance, 30% as unchanged drug, 60% as metabolites); fecal (~10%); biliary minor.
Renal: butalbital ~60% unchanged; codeine ~90% as metabolites (free and conjugated morphine, norcodeine); caffeine <2% unchanged, ~80% as metabolites (paraxanthine, theobromine, theophylline) via renal excretion. Biliary/fecal: minimal.
~20% bound to albumin. Low binding reduces drug interactions.
Butalbital: ~45% (albumin); codeine: ~7–25% (albumin); caffeine: ~10–30% (albumin).
2-3 L/kg (306 L total). Indicates extensive tissue distribution, including CNS penetration.
Butalbital: 0.8 L/kg; codeine: 3–4 L/kg; caffeine: 0.5–0.7 L/kg. Clinical meaning: codeine's high Vd indicates extensive tissue distribution; butalbital and caffeine are more confined to extracellular water.
Oral: 70-75% (first-pass metabolism); IM: 100%; rectal: ~78% relative to oral; IV: 100%.
Oral: butalbital ~90%; codeine ~90% (but extensive first-pass metabolism to morphine); caffeine ~100%.
For Cr Cl < 30 m L/min: increase dosing interval to 12 hours; maximum dose 200 mg/day. For Cr Cl < 10 m L/min: not recommended.
No specific guidelines available. Use with caution in renal impairment; consider reducing dose or extending interval. Monitor for CNS depression and constipation. For GFR < 30 m L/min, use is not recommended.
Child-Pugh Class B: reduce dose by 50% and extend interval to 12 hours. Child-Pugh Class C: not recommended.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate hepatic impairment (Child-Pugh A or B), use with caution; consider reducing dose or extending interval. Monitor for excessive sedation.
1-2 mg/kg/dose every 4-6 hours, not to exceed 8 mg/kg/day or 400 mg/day (whichever less). Not recommended for children < 12 years for post-operative pain.
Not recommended for use in children under 12 years of age. For children 12-18 years, weight-based dosing for codeine: 0.5-1 mg/kg codeine component every 4-6 hours as needed; maximum codeine dose 60 mg/dose. Butalbital and caffeine dosing not established in pediatrics; alternative therapy recommended.
Elderly (>75 years): use lowest effective dose, maximum 300 mg/day; extend dosing interval to 6-8 hours due to decreased clearance.
Start at the lower end of the dosing range (e.g., 1 capsule every 6 hours as needed). Monitor for increased sensitivity to CNS depressant effects, falls, confusion, and constipation. Consider reducing total daily dose. Avoid in frail elderly.
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 2D6 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; SEROTONIN SYNDROME; HEPATIC TOXICITY
Codeine is contraindicated in children younger than 12 years for pain relief, and contraindicated in children younger than 18 years for tonsillectomy/adenoidectomy due to risk of fatal respiratory depression.
Risk of serotonin syndrome when used with serotonergic drugs; risk of seizures in patients with epilepsy or those taking medications that lower seizure threshold; anaphylactic reactions; opioid-induced hyperalgesia; adrenal insufficiency; complex regional pain syndrome; withdrawal symptoms upon discontinuation.
Risk of respiratory depression; addiction and abuse potential; acetaminophen hepatotoxicity (dose-dependent); avoid in patients with severe hepatic impairment; CYP2D6 ultra-rapid metabolizers may experience toxicity with codeine; butalbital can cause dependence and withdrawal; avoid abrupt discontinuation; may impair mental/physical abilities.
Hypersensitivity to tramadol; acute or severe bronchial asthma; significant respiratory depression; gastrointestinal obstruction (including paralytic ileus); concurrent use of MAOIs or within 14 days of MAOI discontinuation; ethanol intoxication; severe hepatic impairment; use in children <12 years for postoperative tonsillectomy/adenoidectomy; known CYP2D6 ultra-rapid metabolizers.
Hypersensitivity to any component; severe respiratory depression; acute or severe asthma; paralytic ileus; known CYP2D6 ultrarapid metabolizers; children <12 years (codeine); use after tonsillectomy/adenoidectomy in children <18 years; concurrent MAOI use or within 14 days; porphyria (butalbital).
Avoid alcohol consumption; may enhance CNS depression and increase risk of hepatotoxicity. Grapefruit juice may inhibit CYP2D6 and alter tramadol metabolism; limit intake. High-fat meals may delay absorption of immediate-release formulations but not significantly affect overall exposure.
Avoid grapefruit juice (may increase butalbital levels); limit or avoid caffeine-containing foods/beverages (coffee, tea, chocolate, cola) to prevent additive stimulation.
Tramadol hydrochloride is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased skeletal variations and delayed ossification at maternally toxic doses. Second and third trimesters: Risk of neonatal respiratory depression, serotonin syndrome, and withdrawal if used near term. Avoid prolonged use or high doses.
First trimester: Codeine (FDA Category C) and butalbital (Category C/D near term) may be associated with increased risk of congenital malformations; caffeine (Category C) at high doses may increase risk of miscarriage. Second and third trimesters: Chronic use may lead to fetal dependence, neonatal withdrawal syndrome; butalbital near term may cause neonatal bleeding due to vitamin K deficiency; codeine may cause respiratory depression if used near delivery.
Tramadol and its active metabolite O-desmethyltramadol (M1) are excreted into breast milk. Milk-to-plasma ratio is approximately 2.2 for tramadol and 2.9 for M1. Relative infant dose is estimated at 2.88% of maternal weight-adjusted dose. Although generally considered compatible, monitor infant for sedation, respiratory depression, and withdrawal symptoms. Use lowest effective dose for shortest duration.
Codeine and caffeine are excreted into breast milk; butalbital is present in low levels. M/P ratio for codeine is approximately 2.0; for caffeine, ~0.5-0.7. Use with caution due to risk of infant sedation, respiratory depression, and withdrawal. Consider alternative analgesics; monitor infant for drowsiness, feeding difficulties, or apnea.
Pregnancy increases tramadol clearance due to enhanced hepatic metabolism and glomerular filtration. Dose adjustments are not standardized; however, increased doses may be needed to maintain analgesic efficacy. Use lowest effective dose and avoid during third trimester to prevent neonatal withdrawal and respiratory depression. Consider alternative analgesics if prolonged use required.
Pregnancy can alter pharmacokinetics: increased blood volume, renal clearance, and hepatic metabolism may reduce drug concentrations. Codeine: increased clearance may require dose adjustment; observe for efficacy. Butalbital: limited data; increased metabolism possible. Caffeine: clearance decreases in later pregnancy; avoid high doses. Individualize dosing based on clinical response and avoid fixed-dose combinations if possible.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active M1 metabolite for opioid analgesia; efficacy varies with CYP2D6 phenotype. Avoid concurrent use with MAOIs due to serotonin syndrome risk; use cautiously with SSRIs/SNRIs as additive serotonergic effects may occur. Tramadol lowers seizure threshold; avoid in patients with epilepsy or those taking other seizure threshold-lowering drugs. Renal impairment (Cr Cl < 30 m L/min) requires extended dosing interval (q12h). Do not exceed 400 mg/day (300 mg in elderly >75 years). Onset of analgesia is ~1 hour; peak effect at 2-3 hours.
Monitor respiratory depression risk, especially in elderly or COPD patients; avoid concurrent use with other CNS depressants; assess liver function due to butalbital metabolism; caffeine may exacerbate anxiety or insomnia.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how this medication affects you.,Risk of serotonin syndrome if combined with other serotonergic drugs (e.g., antidepressants, migraine medications); seek immediate medical attention if symptoms like agitation, hallucinations, rapid heart rate, or fever occur.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and sedatives (e.g., benzodiazepines) as they increase risk of respiratory depression and oversedation.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store at room temperature, away from moisture and heat, and out of reach of children.,Report any history of seizures, head injury, or substance abuse to your doctor.
Do not exceed prescribed dose; may cause drowsiness, avoid driving or operating machinery.,Avoid alcohol and other sedatives; risk of severe drowsiness or breathing problems.,Store securely; risk of abuse and dependence; do not share with others.,Report symptoms of withdrawal (e.g., anxiety, insomnia) when discontinuing.,Caffeine content may cause jitteriness, palpitations, or sleep disturbances.
"Concomitant use of tramadol and secobarbital increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. This is due to additive central nervous system depression from both drugs. Patients should be closely monitored for signs of respiratory depression and excessive sedation."
"Coadministration of tramadol, a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), with pargyline, a nonselective monoamine oxidase inhibitor (MAOI), poses a significant risk of serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system, manifesting as altered mental status, autonomic instability, and neuromuscular hyperactivity. Additionally, tramadol's metabolism via CYP2D6 to its active metabolite M1, and use with an MAOI may lead to hypertensive crisis due to enhanced noradrenergic effects."
"Lisuride, a dopamine agonist, and tramadol, an opioid analgesic with serotonergic activity, synergistically increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. The combination may also potentiate CNS depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Concurrent use should be avoided or undertaken with extreme caution due to the heightened risk of serious adverse outcomes."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAMADOL HYDROCHLORIDE vs PHRENILIN WITH CAFFEINE AND CODEINE, answered by our medical review team.
TRAMADOL HYDROCHLORIDE is a Opioid Agonist that works by Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.. PHRENILIN WITH CAFFEINE AND CODEINE is a Opioid Agonist that works by Combination analgesic; butalbital is a barbiturate that potentiates GABA-A activity; acetaminophen inhibits cyclooxygenase (COX) and modulates cannabinoid receptors; caffeine is a nonselective adenosine receptor antagonist; codeine is a prodrug converted to morphine, a mu-opioid agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAMADOL HYDROCHLORIDE and PHRENILIN WITH CAFFEINE AND CODEINE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAMADOL HYDROCHLORIDE is: 50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).. The standard adult dose of PHRENILIN WITH CAFFEINE AND CODEINE is: 1-2 capsules orally every 4 hours as needed, not to exceed 8 capsules per day. Each capsule contains butalbital 50 mg, caffeine 40 mg, and codeine phosphate 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAMADOL HYDROCHLORIDE and PHRENILIN WITH CAFFEINE AND CODEINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAMADOL HYDROCHLORIDE is classified as Category D/X. Tramadol hydrochloride is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased skeletal variations and delayed ossification at maternally to. PHRENILIN WITH CAFFEINE AND CODEINE is classified as Category D/X. First trimester: Codeine (FDA Category C) and butalbital (Category C/D near term) may be associated with increased risk of congenital malformations; caffeine (Category C) at high d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.